Related Experiment Video

Updated: May 25, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner

Paul J Clark1, Alexander J Thompson, David M Vock

  • 1Duke Clinical Research Institute and Department of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA.

Hepatology (Baltimore, Md.)
|February 10, 2012
PubMed
Abstract

Insights

Hepatitis C virus genotype 3 (HCV G3) uniquely disrupts late cholesterol synthesis, causing low blood cholesterol. This resolves after successful treatment, unlike HCV genotype 2.

Area of Science:

  • Hepatology
  • Virology
  • Metabolomics

Background:

  • Hepatitis C virus (HCV) impacts host cholesterol metabolism, leading to hypocholesterolemia, hepatic steatosis, and insulin resistance.
  • The precise mechanisms of genotype-dependent clinical sequelae remain unclear, though hypocholesterolemia often resolves post-treatment.

Purpose of the Study:

  • To investigate genotype-specific alterations in cholesterol metabolism by HCV.
  • To determine if these metabolic perturbations resolve after achieving sustained viral response (SVR).

Main Methods:

  • Utilized a targeted cholesterol metabolomic platform to analyze paired sera from HCV genotype 2 (G2) and G3 patients.
  • Compared baseline sterol metabolite levels between G2 and G3, and assessed changes following antiviral therapy.
  • Correlated sterol metabolites with insulin resistance and urine oxidative stress markers.

Main Results:

  • HCV G3 patients exhibited lower baseline levels of distal sterol metabolites (e.g., cholesterol, 7-dehydrocholesterol) compared to G2 patients.
  • HCV G3 patients achieving SVR showed increased levels of distal metabolites, while proximal metabolite lanosterol remained unchanged.
  • Lanosterol levels were preserved in HCV G3 patients post-SVR, unlike distal metabolites.

Conclusions:

  • HCV G3 selectively interferes with the late stages of cholesterol synthesis, distinct from HCV G2.
  • The observed distal sterol metabolite reduction and lanosterol preservation in HCV G3 are resolved upon achieving SVR.
  • Preserved lanosterol suggests ongoing HMG-CoA reductase proteolysis, potentially hindering compensatory cholesterol synthesis and explaining persistent hypocholesterolemia in chronic HCV G3 infection.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...